Shares of Phreesia (NYSE:PHR) hit a new 52-week high on Thursday . The stock traded as high as $34.35 and last traded at $34.31, with a volume of 126747 shares. The stock had previously closed at $32.36.
PHR has been the topic of several research reports. Raymond James initiated coverage on Phreesia in a research report on Thursday, December 19th. They issued an “outperform” rating and a $33.00 target price on the stock. Zacks Investment Research lowered Phreesia from a “buy” rating to a “hold” rating in a research report on Tuesday. ValuEngine lowered Phreesia from a “buy” rating to a “hold” rating in a research report on Thursday, October 31st. Cantor Fitzgerald initiated coverage on Phreesia in a research report on Wednesday, January 8th. They issued an “overweight” rating and a $32.00 target price on the stock. Finally, KeyCorp initiated coverage on Phreesia in a research report on Thursday, January 30th. They issued an “overweight” rating and a $36.00 target price on the stock. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Phreesia presently has an average rating of “Buy” and an average target price of $31.78.
The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.01 and a current ratio of 4.01. The stock has a fifty day moving average price of $28.93 and a 200 day moving average price of $27.71.
Phreesia (NYSE:PHR) last issued its quarterly earnings data on Tuesday, December 10th. The company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.03. The company had revenue of $32.80 million for the quarter, compared to analyst estimates of $29.48 million. Phreesia’s revenue for the quarter was up 32.3% on a year-over-year basis. Analysts expect that Phreesia will post -0.43 earnings per share for the current year.
In other news, CEO Chaim Indig sold 80,000 shares of the stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $33.11, for a total transaction of $2,648,800.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Michael Weintraub sold 10,680 shares of the stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $32.51, for a total value of $347,206.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,554,757 shares of company stock worth $63,956,423.
Hedge funds and other institutional investors have recently modified their holdings of the company. Altshuler Shaham Ltd bought a new stake in Phreesia during the 4th quarter valued at approximately $29,000. Bank of Montreal Can bought a new stake in Phreesia during the 4th quarter valued at approximately $33,000. Russell Investments Group Ltd. bought a new stake in Phreesia during the 3rd quarter valued at approximately $47,000. Victory Capital Management Inc. bought a new stake in Phreesia during the 4th quarter valued at approximately $53,000. Finally, Citigroup Inc. boosted its stake in Phreesia by 339.2% during the 4th quarter. Citigroup Inc. now owns 2,073 shares of the company’s stock valued at $55,000 after purchasing an additional 1,601 shares during the period. 51.49% of the stock is currently owned by institutional investors and hedge funds.
About Phreesia (NYSE:PHR)
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.
Recommended Story: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.